Abstract
We describe the development of a new methodology focusing on 11C-labeling of sulfonyl carbamates in a multicomponent reaction comprised of a sulfonyl azide, an alkyl alcohol, and [11C]CO. A number of 11C-labeled sulfonyl carbamates were synthesized and isolated, and the developed methodology was then applied in the preparation of a biologically active molecule. The target compound was obtained in 24±10 % isolated radiochemical yield and was evaluated for binding properties in a tumor cell assay; in vivo biodistribution and imaging studies were also performed. This represents the first successful radiolabeling of a non-peptide angiotensin II receptor subtype 2 agonist, C21, currently in clinical trials for the treatment of idiopathic pulmonary fibrosis.
Original language | English |
---|---|
Pages (from-to) | 566-573 |
Number of pages | 8 |
Journal | ChemistryOpen |
Volume | 5 |
Issue number | 6 |
Early online date | 5 Oct 2016 |
DOIs | |
Publication status | Published - 16 Dec 2016 |
Funding
This work was supported by the Carl Tryggers Foundation for Scientific Research (CTS13:333, CTS14:356), Cancerfonden (Swedish Cancer Society, 2014/474), Vetenskapsrådet Swedish Research Council (2015-02509), and Uppsala University.
Keywords
- AT2R agonists
- multicomponent reactions
- radiochemistry
- sulfonyl azides
- sulfonyl carbamates